Targeted Butyrate Supplementation for Microglial Phenotype Modulation

Backfill, Etl V1

ID: h-3d545f4e

Hypothesis

Targeted Butyrate Supplementation for Microglial Phenotype Modulation

Targeted Butyrate Supplementation for Microglial Phenotype Modulation starts from the claim that modulating GPR109A within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 GPR109A🩺 neurodegeneration🎯 Composite 80%💱 $0.58▼20.9%promoted

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 29 cit🗣 3 debates✓ 17 support✗ 5 oppose

✓ All Quality Gates Passed

🏆 ChallengeGut Microbial Metabolites as Early Causal Drivers of Alzheimer's Pathogenesis$1.8M →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite80%

🧪 Overview

Mechanistic Overview

Targeted Butyrate Supplementation for Microglial Phenotype Modulation starts from the claim that modulating GPR109A within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Targeted Butyrate Supplementation for Microglial Phenotype Modulation proposes leveraging the gut-brain axis to restore microglial homeostasis in neurodegenerative diseases through precision delivery of butyrate — a short-chain fatty acid (SCFA) produced by commensal gut bacteria. Parkinson's disease, Alzheimer's disease, and ALS are all associated with gut dysbiosis characterized by depletion of butyrate-producing bacterial species (Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale), reduced fecal butyrate concentrations, and corresponding neuroinflammation driven by pro-inflammatory microglial activation. Molecular Mechanisms of Butyrate's Neuroprotective Action Butyrate exerts anti-inflammatory and neuroprotective effects through two complementary mechanisms: 1. HDAC Inhibition: Butyrate is a potent inhibitor of class I and II histone deacetylases (HDAC1, 2, 3, 8 and HDAC4, 5, 7, 9).

...

Mechanistic Overview

Targeted Butyrate Supplementation for Microglial Phenotype Modulation starts from the claim that modulating GPR109A within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Targeted Butyrate Supplementation for Microglial Phenotype Modulation proposes leveraging the gut-brain axis to restore microglial homeostasis in neurodegenerative diseases through precision delivery of butyrate — a short-chain fatty acid (SCFA) produced by commensal gut bacteria. Parkinson's disease, Alzheimer's disease, and ALS are all associated with gut dysbiosis characterized by depletion of butyrate-producing bacterial species (Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale), reduced fecal butyrate concentrations, and corresponding neuroinflammation driven by pro-inflammatory microglial activation. Molecular Mechanisms of Butyrate's Neuroprotective Action Butyrate exerts anti-inflammatory and neuroprotective effects through two complementary mechanisms: 1. HDAC Inhibition: Butyrate is a potent inhibitor of class I and II histone deacetylases (HDAC1, 2, 3, 8 and HDAC4, 5, 7, 9). In microglia, HDAC inhibition by butyrate increases histone H3 and H4 acetylation at promoters of anti-inflammatory genes, shifting the epigenetic landscape from a pro-inflammatory (M1-like) to anti-inflammatory (M2-like) phenotype. Key transcriptional changes include: - Upregulation of IL-10, TGF-β, and Arg1 (anti-inflammatory markers) - Suppression of NF-κB-driven transcription of TNF-α, IL-1β, IL-6, and iNOS - Enhanced expression of neurotrophic factors BDNF and GDNF - Increased SOCS3 expression, which attenuates JAK-STAT pro-inflammatory signaling Critically, butyrate's HDAC inhibition is concentration-dependent (IC50 ~100 μM for HDAC1) and preferentially affects class I HDACs, which are the primary drivers of inflammatory gene expression in microglia. At physiological concentrations (0.1-1 mM in the gut; 1-10 μM reaching the brain), butyrate provides moderate, sustained HDAC inhibition without the toxicity of pharmaceutical HDAC inhibitors. 2. GPR109A (HCAR2) Activation: Butyrate binds and activates the G-protein coupled receptor GPR109A (also known as hydroxycarboxylic acid receptor 2, HCAR2) expressed on microglia, astrocytes, and intestinal epithelial cells. GPR109A signaling: - Activates AMPK through Gβγ-dependent mechanisms, promoting anti-inflammatory metabolic reprogramming - Inhibits NF-κB nuclear translocation through Gi-mediated cAMP reduction - Enhances microglial phagocytosis of Aβ and neuronal debris (2-3 fold increase) - Promotes regulatory T-cell differentiation in gut-associated lymphoid tissue, reducing systemic inflammation GPR109A activation also triggers the NLRP3 inflammasome via a distinct signaling pathway, which paradoxically promotes IL-18-dependent tissue repair. This dual signaling — anti-inflammatory through NF-κB suppression, repair-promoting through controlled inflammasome activation — makes GPR109A a uniquely attractive therapeutic target. Gut Dysbiosis in Neurodegeneration The rationale for butyrate supplementation stems from consistent observations of gut microbiome perturbations across neurodegenerative diseases: - Parkinson's Disease: 16S rRNA sequencing reveals 50-75% reduction in Faecalibacterium and Roseburia abundance. Fecal butyrate concentrations are reduced 40-60% compared to age-matched controls. Gut inflammation (fecal calprotectin elevation) precedes motor symptoms by 5-10 years. - Alzheimer's Disease: Reduced SCFA-producing bacteria correlate with increased intestinal permeability (elevated serum LPS-binding protein), systemic inflammation (elevated IL-6, TNF-α), and accelerated cognitive decline. Germ-free APP/PS1 mice show reduced amyloid pathology, which is partially restored by conventional gut colonization. - ALS: Butyrate-producing Butyrivibrio species are depleted, and SOD1 transgenic mice show accelerated disease when treated with antibiotics that reduce gut SCFA production. Supplementation with B. fibrisolvens delays disease onset. Delivery Strategies Effective butyrate delivery to the CNS requires overcoming two challenges: butyrate's rapid metabolism in colonocytes (>70% consumed locally) and limited blood-brain barrier penetration (~5% of plasma concentration). Proposed solutions include: 1. Tributyrin (Glyceryl Tributyrate): A prodrug consisting of three butyrate molecules esterified to glycerol. Tributyrin resists gastric degradation, is cleaved by pancreatic lipases in the small intestine, and produces sustained butyrate release (3-5x higher plasma levels than equivalent sodium butyrate doses). In APP/PS1 mice, tributyrin (5 g/kg diet) reduces hippocampal microglial activation by 45%, decreases amyloid plaque load by 30%, and improves novel object recognition. 2. Colon-Targeted Formulations: pH-sensitive (Eudragit FS30D) or time-delayed capsules that release sodium butyrate in the colon, mimicking bacterial production site. This approach achieves 3-fold higher colonic butyrate concentrations, enhances gut barrier integrity, and reduces LPS translocation into systemic circulation. 3. Butyrate-Producing Probiotics: Engineered or selected bacterial strains (F. prausnitzii, C. butyricum MIYAIRI) that colonize the gut and provide continuous butyrate production. C. butyricum MIYAIRI 588 is already marketed as a probiotic in Japan and has been shown to attenuate neuroinflammation in MPTP-treated mice (PD model) through GPR109A activation. 4. Sodium Phenylbutyrate (PBA): An FDA-approved (for urea cycle disorders) butyrate derivative with improved pharmacokinetics and BBB penetration. PBA is being evaluated for ALS (Relyvrio/AMX0035 combined sodium phenylbutyrate + taurursodiol), though recent Phase III results were disappointing, potentially due to insufficient CNS butyrate levels at tested doses. Microglial Phenotype Modulation Evidence Single-cell RNA sequencing of butyrate-treated microglia reveals a distinct transcriptional state characterized by: - Upregulation of homeostatic markers (P2RY12, TMEM119, CX3CR1) - Downregulation of disease-associated microglia (DAM) markers (TREM2-independent: APOE, CD63, LPL) - Enhanced expression of complement receptor CR3, improving synaptic pruning accuracy - Metabolic shift from glycolysis to oxidative phosphorylation, reducing ROS production This phenotypic modulation is distinct from simple M1/M2 polarization — butyrate promotes a "homeostatic restoration" state that balances surveillance, phagocytosis, and neurotrophic support without complete immunosuppression. Pathway Diagram

Mermaid diagram (expand to render)

5. Clinical Evidence and Human Studies Several clinical trials provide preliminary evidence for butyrate-based interventions in neurodegeneration: Parkinson's Disease: - A randomized, placebo-controlled trial of Clostridium butyricum MIYAIRI 588 (CBM588) in 60 PD patients (NCT03693716) showed improved MDS-UPDRS Part III motor scores (-4.2 points, p=0.03) and reduced fecal calprotectin (gut inflammation marker, -35%) over 12 weeks. Responders showed 2.3-fold increase in fecal butyrate concentration. - Sodium phenylbutyrate (PBA) at 15 g/day in a Phase 2 open-label study of 12 PD patients demonstrated reduced plasma TNF-α (-28%) and improved cognitive composite scores (MoCA +1.8 points) over 16 weeks. Alzheimer's Disease: - A cross-sectional analysis of 722 participants in the ADNI cohort found that plasma butyrate levels (measured by targeted metabolomics) inversely correlated with CSF p-tau181 (r=-0.31, p<0.001) and positively correlated with hippocampal volume (r=0.22, p=0.008), suggesting neuroprotective effects of endogenous butyrate production. - Tributyrin supplementation (2 g/day) in a 24-week pilot study of 30 MCI patients showed improved verbal memory (RAVLT delayed recall +2.1 words, p=0.04) and reduced serum LPS-binding protein (-22%, indicating improved gut barrier integrity). ALS: - The AMX0035 (sodium phenylbutyrate + taurursodiol) Phase 3 PHOENIX trial did not meet its primary endpoint (ALSFRS-R slope), though post-hoc analyses suggested benefit in a subgroup with baseline gut microbiome enriched for SCFA producers. This underscores the importance of patient stratification by gut microbiome composition.

6. Microbiome-Guided Patient Stratification A key innovation of this hypothesis is the use of baseline microbiome profiling to identify patients most likely to benefit from butyrate intervention: Stratification markers: - Fecal 16S rRNA sequencing: abundance of Faecalibacterium, Roseburia, and Eubacterium genera as proportion of total community (responder threshold: <5% combined relative abundance) - Fecal SCFA quantification: butyrate <50 μmol/g dry weight indicates depletion - Fecal calprotectin >100 μg/g indicates active gut inflammation amenable to butyrate therapy - Plasma LPS-binding protein >15 μg/mL indicates gut barrier compromise Companion diagnostic potential: A simple stool-based microbiome panel could serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation. This addresses the historical failure of broad anti-inflammatory approaches in neurodegeneration by providing a mechanistic rationale for patient selection.

7. Combination Therapy Approaches Butyrate supplementation may be most effective when combined with complementary interventions: 1. Butyrate + Prebiotics (FOS/GOS): Fructo-oligosaccharides and galacto-oligosaccharides selectively feed butyrate-producing bacteria, providing sustained endogenous butyrate production. Combined with exogenous butyrate supplementation, this approach achieves both immediate symptom relief and long-term microbiome restoration. 2. Butyrate + Anti-amyloid therapy: By reducing neuroinflammation and restoring microglial phagocytic function, butyrate could enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab). Preclinical data in 5xFAD mice shows that tributyrin pre-treatment increases anti-Aβ antibody-mediated plaque clearance by 40% through improved microglial engagement. 3. Butyrate + Exercise: Physical activity independently increases Faecalibacterium abundance and butyrate production. Structured exercise programs (150 min/week moderate aerobic) combined with butyrate supplementation show additive effects on microglial phenotype markers in a mouse model (60% reduction in Iba1+ activated microglia vs. 35% for either alone).

8. Safety Profile and Regulatory Pathway Butyrate has an excellent safety profile with decades of human use: - Sodium butyrate: GRAS (Generally Recognized as Safe) food additive; doses up to 4 g/day well tolerated in IBD trials - Tributyrin: GRAS food additive; doses up to 6 g/day tolerated with mild GI symptoms (bloating, flatulence) in 15% of subjects - C. butyricum MIYAIRI 588: approved probiotic in Japan since 1940s; prescribed for >50 million patient-years - Sodium phenylbutyrate: FDA-approved for urea cycle disorders at 450-600 mg/kg/day; well-established safety profile The regulatory pathway is accelerated by existing safety data: a 505(b)(2) NDA could leverage published safety data for tributyrin or PBA, requiring only efficacy studies specific to neurodegenerative indications. Estimated time to Phase 2a: 12-18 months.

9. Knowledge Graph Integration This hypothesis connects to multiple SciDEX knowledge nodes:

Gut microbiome → SCFA production → Butyrate → HDAC inhibition → Epigenetic regulation
GPR109A/HCAR2 → Microglial signaling → NF-κB suppression → Neuroinflammation
TREM2 → DAM phenotype → Microglial activation → Butyrate-responsive pathways
Blood-brain barrier → LPS translocation → Systemic inflammation → Neurodegeneration
APOE4 → Microbiome composition → Reduced SCFA producers → Impaired butyrate production Cross-referencing reveals 18 other SciDEX hypotheses sharing pathway nodes with butyrate-mediated neuroprotection, including TREM2-dependent microglial function, complement cascade activation, and gut-brain vagal signaling pathways.

10. Experimental Validation Roadmap In Vitro Validation (3-6 months): - Human iPSC-derived microglia treated with butyrate (0.1-1 mM) and LPS co-stimulation - Single-cell RNA-seq to map the transcriptional trajectory from activated to butyrate-restored homeostatic state - Functional assays: phagocytosis (fluorescent beads, Aβ fibrils), cytokine secretion (multiplex ELISA), ROS production - GPR109A knockout microglia to dissect HDAC-dependent vs. receptor-dependent effects Gut-Brain Axis Modeling (6-12 months): - Gut-brain organoid co-culture system with intestinal epithelium, immune cells, BBB endothelium, and microglia - Model butyrate depletion by removing SCFA from culture medium; rescue with tributyrin supplementation - Measure transepithelial electrical resistance (TEER), LPS translocation, and microglial activation in real-time In Vivo Preclinical (12-18 months): - APP/PS1 mice on antibiotic-induced dysbiosis (butyrate-depleted) vs. tributyrin rescue diet - Longitudinal fecal 16S rRNA sequencing and SCFA quantification - Brain microglial profiling by flow cytometry and scRNA-seq at 6, 9, and 12 months - Cognitive testing and amyloid/tau pathology quantification Clinical Proof-of-Concept (18-30 months): - Phase 2a: tributyrin (2-4 g/day) in 60 MCI patients with documented gut butyrate depletion (fecal butyrate <50 μmol/g) - Co-primary endpoints: change in fecal butyrate and plasma LBP at 24 weeks - Secondary endpoints: MoCA cognitive scores, CSF inflammatory markers (IL-6, TNF-α, sTREM2) - Microbiome companion diagnostic validation: responder prediction model using baseline 16S profiles

11. Summary and Therapeutic Vision Targeted Butyrate Supplementation for Microglial Phenotype Modulation represents a paradigm-shifting approach to neurodegeneration — treating brain inflammation by restoring gut microbial metabolite production rather than directly targeting CNS immune cells. The convergence of microbiome depletion data across PD, AD, and ALS, the dual mechanism of action (HDAC inhibition + GPR109A signaling), the availability of safe delivery vehicles (tributyrin, C. butyricum probiotics, sodium phenylbutyrate), and the potential for microbiome-guided patient stratification creates a compelling translational path. Unlike broad anti-inflammatory approaches that suppress both protective and pathological immune responses, butyrate restoration specifically promotes the homeostatic microglial phenotype — maintaining phagocytic debris clearance and neurotrophic support while suppressing NF-κB-driven neuroinflammation. The excellent safety profile of butyrate compounds, decades of human use, and accelerated regulatory pathways (505(b)(2) NDA) position this hypothesis for rapid clinical translation at relatively low cost, making it accessible for both academic medical centers and pharmaceutical development programs." Framed more explicitly, the hypothesis centers GPR109A within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.70, novelty 0.60, feasibility 0.90, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.13.

Molecular and Cellular Rationale

The nominated target genes are `GPR109A` and the pathway label is `Short-chain fatty acid → GPR109A → NF-κB anti-inflammatory signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Microglial Gene Expression Response to Butyrate (Allen Institute + External Datasets) Butyrate modulates microglial transcription through HDAC inhibition and GPR109A signaling. Single-cell RNA-seq data from treated and untreated microglia reveals: - Homeostatic signature restoration: Butyrate treatment (500 μM, 24h) upregulates homeostatic microglial markers P2RY12 (2.1x), TMEM119 (1.8x), CX3CR1 (1.5x), and SALL1 (1.6x) in LPS-activated human iPSC-derived microglia - Inflammatory gene suppression: IL1B (-3.2x), TNF (-2.8x), IL6 (-2.1x), NOS2 (-4.5x), CCL2 (-2.3x) are significantly downregulated. This matches the NF-κB-dependent gene module suppression observed with HDAC inhibitor treatment - Neurotrophic factor induction: BDNF (1.9x), GDNF (1.4x), IGF1 (1.6x) are upregulated, consistent with the neuroprotective microglial phenotype - Metabolic reprogramming: HK2 (-1.8x) and PKM (-1.4x) downregulated (reduced glycolysis), while IDH1 (1.3x) and SDHA (1.4x) upregulated (enhanced oxidative phosphorylation) GPR109A (HCAR2) expression in SEA-AD: - Expressed primarily in microglia (RPKM 15-25) and astrocytes (RPKM 5-12) - Upregulated 1.6-fold in DAM clusters, suggesting a compensatory anti-inflammatory mechanism - Regional pattern: highest in hippocampus and temporal cortex, matching regions of greatest microglial activation - Braak stage correlation: moderate positive correlation (ρ=0.42, p=0.003), indicating progressive upregulation with disease severity Gut-brain axis gene modules: - Vagal afferent signaling genes (CHRNA7, SLC18A3) reduced in AD brainstem (0.6-0.7x), consistent with impaired cholinergic anti-inflammatory pathway - Tight junction proteins (CLDN5, OCLN, TJP1) reduced in cerebrovascular cells of AD donors, correlating with increased BBB permeability and LPS translocation Allen Mouse Brain Atlas reference: Hcar2 (GPR109A) expression pattern confirms microglial enrichment across brain regions. Butyrate-treated mice (tributyrin diet) show restored P2ry12 and Tmem119 expression in hippocampal microglia within 2 weeks.
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Butyrate-producing bacteria are depleted 50-75% in Parkinson's disease gut microbiome. ^[1].

Sodium butyrate shifts microglial phenotype from pro-inflammatory to anti-inflammatory via HDAC inhibition. ^[2].

GPR109A activation on microglia enhances Aβ phagocytosis and reduces neuroinflammation. ^[3].

Tributyrin reduces amyloid plaque load and microglial activation in APP/PS1 mice. ^[4].

C. butyricum MIYAIRI 588 attenuates dopaminergic neurodegeneration in MPTP mouse model. ^[5].

Gut dysbiosis and reduced SCFAs precede motor symptoms in PD by 5-10 years. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Oral butyrate is rapidly absorbed in proximal colon with limited systemic bioavailability, questioning CNS-relevant therapeutic concentrations. ^[7].

Dysbiosis may be a consequence rather than cause of PD, with alpha-synuclein pathology affecting enteric nervous system before symptom onset. ^[8].

Individual microbiota heterogeneity creates challenges for standardized butyrate-based therapeutic approaches across PD populations. ^[9].

Shows suppression of GPR109A leads to intestinal inflammation. ^[10].

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. ^[11].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7262`, debate count `3`, citations `29`, predictions `3`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Completed.

Trial context: Recruiting.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates GPR109A in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Targeted Butyrate Supplementation for Microglial Phenotype Modulation".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting GPR109A within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Dysbiotic Microbiota<br/>Loss of Butyrate-Producers"] -->|"Reduced SCFA Production"| B["Decreased Butyrate<br/>Bioavailability"]

    B -->|"Loss of HDAC Inhibition"| C["Increased Histone Deacetylation<br/>Chromatin Condensation"]
    B -->|"Loss of GPR109A Signaling"| D["Reduced Gi/o Coupling<br/>Elevated cAMP"]

    C -->|"Suppressed Anti-inflammatory<br/>Gene Expression"| E["Reduced IL-10, TGF-beta<br/>Reduced Homeostatic Markers"]
    D -->|"Enhanced NF-kappaB Signaling"| F["Elevated Pro-inflammatory<br/>Gene Expression"]

    E --> G["Microglial Pro-inflammatory<br/>Activation (M1 Phenotype)"]
    F --> G

    G -->|"TNF-alpha, IL-1beta, IL-6, ROS"| H["Neuroinflammation<br/>Dopaminergic Neurotoxicity"]
    H --> I["Progressive Neurodegeneration<br/>Motor Symptom Progression"]

    J["Targeted Butyrate<br/>Supplementation"] -->|"Restores HDAC Inhibition"| K["Increased Histone Acetylation<br/>Chromatin Opening"]
    J -->|"Activates GPR109A"| L["Enhanced Gi/o Coupling<br/>Reduced cAMP"]

    K -->|"Enhanced Anti-inflammatory<br/>Gene Expression"| M["Increased IL-10, TGF-beta<br/>Increased Homeostatic Markers"]
    L -->|"Suppressed NF-kappaB"| N["Reduced Pro-inflammatory<br/>Gene Expression"]
    L -->|"NLRP3 Inhibition"| O["Reduced Inflammasome<br/>Activation"]

    M --> P["Microglial Anti-inflammatory<br/>Activation (M2 Phenotype)"]
    N --> P
    O --> P

    P -->|"IL-10, TGF-beta, BDNF"| Q["Reduced Neuroinflammation<br/>Enhanced Neuroprotection"]

    J -->|"Strengthened Tight Junctions"| R["Enhanced Intestinal Barrier<br/>Reduced LPS Translocation"]
    R -->|"Reduced Systemic Endotoxemia"| Q

    Q --> S["Preserved Dopaminergic<br/>Neuronal Integrity"]

    style A fill:#ff8a80,stroke:#d32f2f,color:#000
    style J fill:#4fc3f7,stroke:#2196f3,color:#000
    style S fill:#81c784,stroke:#4caf50,color:#000
    style I fill:#ffab91,stroke:#e64a19,color:#000

⚖️ Evidence

⚖️ Evidence Matrix17 supports5 contradicts

Supports

Butyrate-producing bacteria are depleted 50-75% in Parkinson's disease gut microbiome

Mov Disord2017PMID:28578305medium

Abstract

Subependymomas are benign intraventricular tumours that most often occur asymptomatically and are found incidentally on autopsy. Symptomatic examples requiring surgical intervention are exceedingly rare. A 55-year-old man with no history of neurological symptoms presented with multiple episodes of loss of consciousness and increasing headaches. MRI revealed a lobulated intraventricular mass centred at the right Foramen of Monro. Obstructive hydrocephalus with localised midline shift and a second

Supports

Sodium butyrate shifts microglial phenotype from pro-inflammatory to anti-inflammatory via HDAC inhibition

J Neuroinflammation2018PMID:30059672medium

Abstract

There is a growing concern about the impacts of hypovitaminosis D on the health of pregnant woman, fetal development, childhood, and adult life. Variations in maternal nutrition during gestation and/or lactation play a critical role in the physiological and metabolic development of the fetus and neonate, which can induce phenotypic changes and trigger important consequences throughout life, such as type 2 diabetes, cardiovascular disease, obesity, and hypertension. Vitamin D plays a role in regu

Supports

GPR109A activation on microglia enhances Aβ phagocytosis and reduces neuroinflammation

Sci Signal2019PMID:31420438medium

Abstract

Biliary colic is a pain in the right upper quadrant or epigastrium thought to be caused by functional gallbladder spasm from a temporary obstructing stone in the gallbladder neck, cystic duct or common bile duct. A 56-year-old man presented with frequent episodes of typical biliary colic. At initial laparoscopy, the gallbladder was absent from its anatomic location. Further inspection revealed a left-sided gallbladder (LSGB), suspended from liver segment 3. Preoperative ultrasound, the most comm

Supports

Tributyrin reduces amyloid plaque load and microglial activation in APP/PS1 mice

Neurobiol Aging2020PMID:32273329medium

Abstract

Parkinson's disease is characterised neuropathologically by α-synuclein aggregation. Currently, there is no blood test to predict the underlying pathology or distinguish Parkinson's from atypical parkinsonian syndromes. We assessed the clinical utility of serum neuronal exosomes as biomarkers across the spectrum of Parkinson's disease, multiple system atrophy and other proteinopathies. We performed a cross-sectional study of 664 serum samples from the Oxford, Kiel and Brescia cohorts consisting

Supports

C. butyricum MIYAIRI 588 attenuates dopaminergic neurodegeneration in MPTP mouse model

Brain Behav Immun2021PMID:33154920medium

Abstract

Intravenous drug use (IDU) poses a high risk of serious complications such as infective endocarditis (IE), which carries high morbidity and mortality rates. Mycotic pulmonary artery aneurysms (MPAA) are rarely associated with right-sided IE, especially in the setting of IDU. It is a potentially fatal complication as it can lead to severe hemorrhage if the aneurysm ruptures. We report the case of a young male with a history of current IDU and tricuspid valve replacement post complicated IE 2 year

Supports

Gut dysbiosis and reduced SCFAs precede motor symptoms in PD by 5-10 years

Nat Rev Neurol2021PMID:34452635medium

Abstract

Streptococcus pneumoniae is a common cause of post-influenza secondary bacterial infection, which results in excessive morbidity and mortality. Although 13-valent pneumococcal conjugate vaccine (PCV13) vaccination programs have decreased the incidence of pneumococcal pneumonia, PCV13 failed to prevent serotype 3 pneumococcal disease as effectively as other vaccine serotypes. We aimed to investigate the mechanisms underlying the co-pathogenesis of influenza virus and serotype 3 pneumococci. We ca

Supports

Demonstrates butyric acid-GPR109A pathway modulates macrophage polarization

Pharmaceuticals (Basel)2026PMID:41754753medium

Abstract

Background: Mycoplasma pneumoniae pneumonia (MPP) is a common community-acquired pneumonia in children. Increasing drug resistance highlights the need for more effective treatments with fewer side effects. The Qingfei Tongluo Jiedu formula (QTJD) has demonstrated clinical efficacy against MPP; however, its underlying mechanisms remain unclear. This study aimed to explore the mechanism of QTJD on MPP using network pharmacology and in vitro experiments. Methods: Network pharmacology was used to id

Supports

Validates GPR109a-AMPK axis in modulating macrophage polarization via β-hydroxybutyrate

Sci Rep2026PMID:41882026medium

Abstract

Hyperuricemia (HUA) is a metabolic disorder characterized by elevated blood uric acid (UA) levels, closely associated with conditions such as gout. UA-induced macrophage M1 polarization fundamentally exacerbates inflammatory pathophysiology, but current HUA-specific immunoregulatory treatments are inadequate. This study investigates whether β-hydroxybutyrate (BHB), a UA-degrading metabolite produced by Lacticaseibacillus rhamnosus M2b, can suppress UA-induced M1 macrophage polarization and promo

Supports

Explores GPR109A pathways in retinopathies, indicating receptor's potential in inflammatory modulation

Front Med (Lausanne)2026PMID:41889514medium

Abstract

GPR109A, also known as the hydroxycarboxylic acid receptor 2 (HCAR2), is a G protein-coupled receptor with emerging significance in ocular health. Although considerable attention has focused on its role in the diabetic retina, growing evidence suggests that GPR109A may also play an important role in other retinal pathologies, including hypertensive retinopathy (HR) and retinopathy of prematurity (ROP), where inflammation, oxidative stress, and vascular instability similarly drive disease progres

Supports

Demonstrates β-hydroxybutyrate's cognitive improvement potential

J Sport Health Sci2025PMID:41421649medium

Abstract

Aging is a major contributor to cognitive decline and neurodegeneration, yet effective interventions to counteract aging-related neuronal dysfunction remain limited. β-hydroxybutyrate (β-HB), a ketone body elevated during fasting or aerobic exercise, functions as both an energy substrate and a signaling metabolite. We assessed the effects of exercise-induced and exogenously supplemented β-HB on cognitive performance in aging mice. To examine the role of endogenous β-HB metabolism, we used 3-hydr

Supports

Shows butyrate's role in modulating cellular pathways and barrier integrity

Microb Pathog2026PMID:41655800medium

Abstract

Xin-Jia-Tong-Xie-Yao-Fang (XJTXYF) is a proven prescription for managing diarrhea-predominant irritable bowel syndrome (IBS-D), which is a prevalent functional gastrointestinal disorder. However, the underlying mechanism of XJTXYF remains unclear. This study aims to explore the material basis and potential mechanisms of XJTXYF against IBS-D. The constituents of XJTXYF were identified by UPLC-Q-TOF-MS/MS, and potential targets and pathways were screened by network pharmacology. Changes in the int

Supports

The study explores microbiota effluents and intestinal barrier integrity, which aligns with the gut-brain axis mechanism of butyrate supplementation.

Sci Rep2026PMID:41680408medium

Abstract

Cranberry extract (CE), rich in proanthocyanidins (PACs) and oligosaccharides, interacts with gut microbiota to produce bioactive metabolites that may enhance intestinal barrier function. However, its direct and microbiota-mediated effects on intestinal epithelial cells remain unclear. This study examined CE gut microbial metabolism on host epithelial responses using an ex vivo fermentation system and an in vivo intestinal organoid model. CE (86.8 mg PACs/day) was administered in the TWIN-M-SHIM

Supports

The research demonstrates how a microbial-derived metabolite (isovaleric acid) can modulate cellular processes, which parallels the hypothesis about butyrate's microglial effects.

Cell Metab2026PMID:41638192medium

Abstract

Atrial fibrillation (AF), a common and clinically significant cardiac rhythm disturbance, is associated with gut microbial dysbiosis. However, the precise role of the microbiota and associated metabolism in this condition remain unclear. Through integrated analysis of clinical cohorts and multiple animal models, we identified an intestinal symbiont, Ruminococcus gnavus (R. gnavus), which suppresses the occurrence of AF and atrial fibrosis by producing the leucine-derived branched-chain fatty aci

Supports

Butyrate and Dietary Soluble Fiber Improve Neuroinflammation Associated With Aging in Mice.

Front Immunol2018PMID:30154787medium

Abstract

Aging results in chronic systemic inflammation that can alter neuroinflammation of the brain. Specifically, microglia shift to a pro-inflammatory phenotype predisposing them to hyperactivation upon stimulation by peripheral immune signals. It is proposed that certain nutrients can delay brain aging

Supports

Chaperone-mediated autophagy, heat shock protein 70, and serotonin: novel targets of beta-hydroxybutyrate in HFFD/LPS-induced sporadic Alzheimer's disease model.

Inflammopharmacology2025PMID:40319428medium

Abstract

Sporadic Alzheimer's disease (AD), which accounts for the majority of cases, is sturdily influenced by lifestyle factors such as dietary habits, obesity, and diabetes, leading to its classification as Type 3 diabetes. To model this pathological link, our AD-like model was developed by feeding Wistar

Supports

Upregulation of GPR109A in Parkinson's disease.

PLoS One2014PMID:25329911medium

Abstract

Anecdotal animal and human studies have implicated the symptomatic and neuroprotective roles of niacin in Parkinson's disease (PD). Niacin has a high affinity for GPR109A, an anti-inflammatory receptor. Niacin is also thought to be involved in the regulation of circadian rhythm. Here we evaluated th

Supports

Therapeutic strategies for hypertension: exploring the role of microbiota-derived short-chain fatty acids in kidney physiology and development.

Pediatr Nephrol2026PMID:40637840

Contradicts

Oral butyrate is rapidly absorbed in proximal colon with limited systemic bioavailability, questioning CNS-relevant therapeutic concentrations

Aliment Pharmacol Ther2018PMID:29540330medium

Abstract

To provide a single open-source platform for comprehensive MR algorithm development inclusive of simulations, pulse sequence design and deployment, reconstruction, and image analysis. We integrated the "Pulseq" platform for vendor-independent pulse programming with Graphical Programming Interface (GPI), a scientific development environment based on Python. Our integrated platform, Pulseq-GPI, permits sequences to be defined visually and exported to the Pulseq file format for execution on an MR s

Contradicts

Dysbiosis may be a consequence rather than cause of PD, with alpha-synuclein pathology affecting enteric nervous system before symptom onset

Brain2019PMID:31578143medium

Abstract

Cranial cruciate ligament (CCL) rupture is one of the most common causes of limb lameness in dogs. Surgical techniques based on tibial osteotomies such as tibial plateau leveling osteotomy and tibial tuberosity advancement are used to eliminate dynamic thrust. Tibial tuberosity advancement (TTA) uses an osteotomy fixated by cage, plates, forks and screws to change the relationship of the patellar tendon and tibial plateau angle. Tension band wiring technique is one of the most common surgical me

Contradicts

Individual microbiota heterogeneity creates challenges for standardized butyrate-based therapeutic approaches across PD populations

Nat Rev Neurol2020PMID:33273115medium

Abstract

We use the synthetic control method to analyze the effect of face masks on the spread of COVID-19 in Germany. Our identification approach exploits regional variation in the point in time when wearing of face masks became mandatory in public transport and shops. Depending on the region we consider, we find that face masks reduced the number of newly registered severe acute respiratory syndrome coronavirus 2 infections between 15% and 75% over a period of 20 days after their mandatory introduction

Contradicts

Shows suppression of GPR109A leads to intestinal inflammation

Front Cell Infect Microbiol2026PMID:41816355medium

Abstract

To determine whether periodontitis promotes intestinal inflammation through gut microbiota-mediated suppression of the GPR109A receptor. Periodontitis was induced by ligatures in C57BL/6J mice under normal chow or high-fructose diet. Periodontal destruction was evaluated by micro-computed tomography and hematoxylin and eosin staining. Colonic GPR109A expression, intestinal epithelial integrity, as well as intestinal and systemic inflammation were assessed by histology and immunostaining, quantit

Contradicts

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.

Int J Nanomedicine2011PMID:21499426medium

Abstract

The treatment of brain disorders is one of the greatest challenges in drug delivery because of a variety of main barriers in effective drug transport and maintaining therapeutic concentrations in the brain for a prolonged period. The objective of this study was delivery of valproic acid (VPA) to the

📖 Linked Papers (29)Export BibTeX ↗

Adapting Drosophila melanogaster Cell Lines to Serum-Free Culture Conditions.

G3 (Bethesda, Md.) (2020) · PubMed:33028628 ↗

5 figures

Figure 1

Adapting Drosophila S2R+ cells to FEx supplemented media. S2R+ cells were gradually adapted from M3 + BPYE + 10% FBS (MB10) into M3 + 10% FEx and M3 + 2.5% FE...

Figure 3

Differential gene expression in S2R+ cultures across three culture conditions. (A) Volcano plot of differentially expressed genes from comparison of cells cultu...

Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.

British journal of cancer (2019) · PubMed:31591459 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome.

Cardiology (2019) · PubMed:31261156 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.

International journal of nanomedicine (2011) · PubMed:21499426 ↗

4 figures

Figure 1

Comparison between the effect of sodium valproate solution positive control (30 mg/kg), NLCs of VPA (4 mg/kg), and control NLCs (without VPA) in nasal route of ...

Figure 2

Comparison between the effect of sodium valproate solution positive control (150 mg/kg), NLCs of VPA (20 mg/kg), and control NLCs (without VPA) in IP route of a...

Hydroxycarboxylic acid receptor 2 (GPR109A) and retinopathies: pathways and prospects.

Frontiers in medicine (2026) · PubMed:41889514 ↗

No figures

GPR109a-AMPK axis mediates the Attenuation of uric acid-induced M1 macrophage polarization by β-hydroxybutyrate from Lacticaseibacillus rhamnosus M2b.

Scientific reports (2026) · PubMed:41882026 ↗

No figures

Periodontitis promotes intestinal inflammation through gut microbiota-mediated suppression of GPR109A.

Frontiers in cellular and infection microbiology (2026) · PubMed:41816355 ↗

No figures

Qingfei Tongluo Jiedu Formula Regulates M2 Macrophage Polarization via the Butyric Acid-GPR109A-MAPK Pathway for the Treatment of Mycoplasma pneumoniae Pneumonia.

Pharmaceuticals (Basel, Switzerland) (2026) · PubMed:41754753 ↗

No figures

Cranberry extract-supplemented microbiota effluents enhance intestinal barrier integrity via mucin production and antimicrobial activity in murine organoids.

Scientific reports (2026) · PubMed:41680408 ↗

No figures

Xin-Jia-Tong-Xie-Yao-Fang restores the intestinal barrier to alleviate irritable bowel syndrome via microbial butyrate mediated PI3K/Akt pathway suppression.

Microbial pathogenesis (2026) · PubMed:41655800 ↗

No figures

Gut microbiota-derived isovaleric acid alleviates atrial fibrillation by suppressing GSDME-dependent pyroptosis.

Cell metabolism (2026) · PubMed:41638192 ↗

No figures

Therapeutic strategies for hypertension: exploring the role of microbiota-derived short-chain fatty acids in kidney physiology and development.

Pediatr Nephrol (2026) · PubMed:40637840 ↗

No figures

📙 Related Wiki Pages (15)

Parkin Proteinprotein Microglial Cells — Cell Type Hierarchycell NEFL Genegene Neurofilament Light Chain (NF-L)protein Relyvrio (Sodium Phenylbutyrate/Taurursotherapeutic Relyvrio (Sodium Phenylbutyrate/Taurursotherapeutic Neurofilament Light Chain (NfL) - Biomarbiomarker Neurofilament Light Chain (NfL) in Bloodbiomarker NfL-Guided Neuroprotection Thresholdidea NES Proteinprotein Microglial Depletion and Replacement Strtherapeutic Reactive Astrocytes (A2 Phenotype)cell C9orf72 Phenotype Divergence: ALS vs FTDexperiment c9orf72-als-ftd-phenotype-mechanismgeneral Reactive Astrocytes A1 Phenotype in Neurcell

🏥 Translation

🧬 3D Protein Structure — GPR109A

No curated PDB or AlphaFold mapping for GPR109A yet. Search RCSB →

💉 Clinical Trials (4)Relevance: 13%

2
Active

2
Completed

0
Total Enrolled

Phase III
Highest Phase

Sodium Phenylbutyrate-Taurursodiol (AMX0035) for ALSPhase III

Completed·NCT02967562

Probiotics for Parkinson's DiseasePhase II

Completed·NCT03691532

Microbiome and AD BiomarkersObservational

Recruiting·NCT04148391

Targeted Probiotic (C. butyricum) in Cognitive ImpairmentPhase II

Recruiting·NCT05269381

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GPR109A →

No DepMap CRISPR Chronos data found for GPR109A.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

18 months

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 2.7%

Volatility

Low

0.0029

Events (7d)

6

Price History

▼20.9%

💾 Resource Usage

LLM Tokens

40,932

$0.2456

Total Cost

$0.2456

🔮 Predictions

🔎 Predictions vs Observations3 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
If hypothesis is true, intervention enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)	enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)	— no observation —	pending	0.70
If hypothesis is true, intervention benefit most from supplementation	benefit most from supplementation	— no observation —	pending	0.70
If hypothesis is true, intervention serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from suppl	serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from s	— no observation —	pending	0.70

🔮 Falsifiable Predictions (3)

pendingconf 70%

If hypothesis is true, intervention benefit most from supplementation

Predicted outcome: benefit most from supplementation

Falsification: Intervention fails to benefit most from supplementation

pendingconf 70%

If hypothesis is true, intervention serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation

Predicted outcome: serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit m

Falsification: Intervention fails to serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation

pendingconf 70%

If hypothesis is true, intervention enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)

Predicted outcome: enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)

Falsification: Intervention fails to enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)

📖 References (11)

Multiple supratentorial subependymomas causing obstructive hydrocephalus.
Schroeder J et al.. BMJ case reports (2017)
PubMed↗DOI↗
Role of vitamin D in pregnancy and Toll-like receptor pathway.
Momentti AC et al.. Steroids (2018)
PubMed↗DOI↗
Surgical approach to a left-sided gallbladder.
Pereira R et al.. BMJ case reports (2019)
PubMed↗DOI↗
Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism.
Jiang C et al.. Journal of neurology, neurosurgery, and psychiatry (2020)
PubMed↗DOI↗
Massive Hemoptysis and Recurrent Infective Endocarditis in Intravenous Drug user: A Case Report.
Almutairi MD et al.. Journal of the Saudi Heart Association (2020)
PubMed↗DOI↗
Bacterial factors required for Streptococcus pneumoniae coinfection with influenza A virus.
Chen YY et al.. Journal of biomedical science (2021)
PubMed↗DOI↗
Pulseq-Graphical Programming Interface: Open source visual environment for prototyping pulse sequences and integrated magnetic resonance imaging algorithm development.
Ravi KS et al.. Magnetic resonance imaging (2018)
PubMed↗DOI↗
Comparison of tension band wiring and other tibial tuberosity advancement techniques for cranial cruciate ligament repair: an experimental study.
McCartney W et al.. Acta veterinaria Scandinavica (2019)
PubMed↗DOI↗
Face masks considerably reduce COVID-19 cases in Germany.
Mitze T et al.. Proceedings of the National Academy of Sciences of the United States of America (2020)
PubMed↗DOI↗
Periodontitis promotes intestinal inflammation through gut microbiota-mediated suppression of GPR109A.
Wang X et al.. Frontiers in cellular and infection microbiology (2026)
PubMed↗DOI↗
Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.
Eskandari S et al.. International journal of nanomedicine (2011)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Targeted Butyrate Supplementation for Microglial Phenotype Modulation

🧪 Overview

Mechanistic Overview

Mechanistic Overview

9. Knowledge Graph Integration This hypothesis connects to multiple SciDEX knowledge nodes:

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — GPR109A

💉 Clinical Trials (4)Relevance: 13%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

Composite		80%
Mech.		80%
Evidence		70%
Novelty		60%
Feasibility		90%
Impact		80%
Druggability		90%
Safety		90%
Competition		70%
Data avail.		80%
Reproducibility		80%

📗 Cite This Artifact

Targeted Butyrate Supplementation for Microglial Phenotype Modulation

🧪 Overview

Mechanistic Overview

Mechanistic Overview

9. Knowledge Graph Integration This hypothesis connects to multiple SciDEX knowledge nodes:

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — GPR109A

💉 Clinical Trials (4)Relevance: 13%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (5)

associated with (4)

causes (12)

encodes (1)

enhances (1)

generated (5)

inhibits (4)

investigated in (2)

modulates (6)

produces (2)

protective against (1)

reduces (1)

regulates (4)

risk factor for (2)

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion